Clinical review report Tenofovir alafenamide (Vemlidy) (Gilead Sciences Canada, Inc.)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of tenofovir alafenamide for the treatment of adults with chronic hepatitis B (CHB) and compensated liver disease.
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | Inglés |
| Published: |
Ottawa, Ontario :
Canadian Agency for Drugs and Technologies in Health
2018.
|
| Subjects: | |
| See on Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820281606719 |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of tenofovir alafenamide for the treatment of adults with chronic hepatitis B (CHB) and compensated liver disease. |
|---|---|
| Physical Description: | 1 online resource (1 PDF file (65 pages)) : illustrations |
